App-Quantinova.ai

Effectiveness of intravenous high-dose methotrexate for prevention of relapse in patients with DLBCL.

Hind Alotaibi - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Methotrexate

Machine learning models to quantify HER2 for real-time tissue image analysis in prospective clinical trials.

Benjamin Glass - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Estradiol/gestodene

Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.

Paolo Caimi - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Carlos A. Gomez-Roca - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Pembrolizumab

Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade (TRG) ≥3 in oesophago-gastric cancer (OGC).

Brindley Sonal Hapuarachi - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Fluorouracil

Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).

Kwee Yong - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Cyclophosphamide

Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.

Jessica Cecile Hassel - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Uveal melanoma

GP100

Active elite rugby participation predicts alterations in right precentral cortical thickness

Thomas Parker - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Traumatic brain injury

N/A

Acute seizure risk in encephalitis analysis and modelling of 436 patients from two independent multi centre cohorts

Greta Wood - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Epilepsy

N/A

Assessment of Olfactory Function in Classical Infratentorial Superficial Siderosis

Natallia Kharytaniuk - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Superficial siderosis

N/A

Autonomic dysfunction after moderate severe traumatic brain injury symptom spectrum and clinical testing outcomes

Lucia Li - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Traumatic brain injury

N/A

Baseline EMBARK Data From EMERGE ENGAGE and PRIME Participants in the EMBARK Redosing Study

Sharon Cohen - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

Aducanumab

Brain Network Centrality Abnormalities Underpin Multiple Sclerosis Disease Course

Antonio Carotenuto - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Characterization and Analysis of Neurologic Adverse Events Associated with COVID 19 Vaccination

Abhilasha Boruah - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Cognitive Processing Speed Predicts Disease Progression in Secondary Progressive Multiple Sclerosis Post Hoc Analysis from the EXPAND Study

Iris-Katharina Penner - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Siponimod

Comparative Effectiveness of Cladribine versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis The MERLYN MavEnclad Real worLd comparative efficacY non iNterventional Study

Wallace Brownlee - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

A Concisely Recorded Ambulatory Assessment for Enhancing Real World Outcomes Research in Duchenne Muscular Dystrophy Development and Validation

Anna Mayhew - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Duchenne muscular dystrophy

N/A

Current Perspectives on the Management of Cervical Dystonia Among Global Clinicians

Hyder Jinnah - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

OnabotulinumtoxinA

Deep learning for prediction of IDH mutation in gliomas a meta analysis of evaluation of diagnostic test performance with a Bayesian approach

Mert Karabacak - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

N/A

Disease activity after cladribine immune reconstitution therapy To repeat or to retreat

Kimberley Allen-Philbey - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cladribine

Filters

45280 Abstracts